Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18975132 | 0.88 | TSHR (0.41) | TSHRMAPK1TP53CYP3A4ALDH1A1 | |
| SCHEMBL18975215 | 0.80 | JAK3 (0.34) | — | |
| SCHEMBL18975131 | 0.74 | TSHR (0.44) | TSHRMAPK1TP53CYP3A4ALDH1A1 | |
| SCHEMBL18975049 | 0.73 | TSHR (0.45) | TSHRMAPK1TP53CYP3A4ALDH1A1 | |
| SCHEMBL18974960 | 0.72 | RAB9A (0.41) | MAPK1LMNAKDM4E | |
| SCHEMBL18975466 | 0.67 | HTT (0.47) | TSHRMAPK1TP53CYP3A4ALDH1A1 | |
| SCHEMBL28978567 | 0.65 | ALDH1A1 (0.61) | TSHRMAPK1TP53CYP3A4ALDH1A1 | |
| SCHEMBL5935743 | 0.65 | TSHR (0.65) | TSHRMAPK1TP53CYP3A4ALDH1A1 | |
| SCHEMBL8959903 | 0.65 | TSHR (0.65) | TSHRMAPK1TP53CYP3A4ALDH1A1 | |
| SCHEMBL27271383 | 0.63 | TSHR (0.57) | TSHRMAPK1TP53CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN LLC (US) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNA7, CHRNA2, CHRNA6 | TSHR 470/4885MAPK1 2945/4885TP53 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.